Telix Pharmaceuticals Limited (NASDAQ: TLX) Stock Competitors & Peer Comparison
See TLX's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for TLX and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| TLX | $11.82 | -4.14% | 4B | -642.39 | -$0.02 | N/A |
| VRTX | $505.75 | -2.07% | 128.4B | 26.58 | $19.03 | N/A |
| REGN | $803.48 | -0.31% | 82.8B | 17.61 | $45.63 | +0.45% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $851.29 | -0.66% | 52.9B | 76.83 | $11.08 | N/A |
| RVMDW | $11.10 | +0.00% | 44B | -1.55 | -$7.21 | N/A |
| RVMD | $203.71 | +0.85% | 43.3B | -23.10 | -$8.82 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ONC | $347.48 | -2.40% | 37.1B | 61.18 | $5.68 | N/A |
| ALNY | $228.65 | +0.67% | 30.6B | 41.20 | $5.55 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
TLX vs VRTX Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, VRTX has a market cap of 128.4B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while VRTX trades at $505.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas VRTX's P/E ratio is 26.58. In terms of profitability, TLX's ROE is -0.02%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, TLX is less volatile compared to VRTX. This indicates lower risk in terms of short-term price fluctuations for TLX.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
TLX vs REGN Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, REGN has a market cap of 82.8B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while REGN trades at $803.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas REGN's P/E ratio is 17.61. In terms of profitability, TLX's ROE is -0.02%, compared to REGN's ROE of +0.14%. Regarding short-term risk, TLX is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for TLX.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
TLX vs VRNA Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas VRNA's P/E ratio is -102.80. In terms of profitability, TLX's ROE is -0.02%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, TLX is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for TLX.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
TLX vs ARGX Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, ARGX has a market cap of 52.9B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while ARGX trades at $851.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas ARGX's P/E ratio is 76.83. In terms of profitability, TLX's ROE is -0.02%, compared to ARGX's ROE of +0.32%. Regarding short-term risk, TLX is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for TLX.Check ARGX's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
TLX vs RVMDW Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, RVMDW has a market cap of 44B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while RVMDW trades at $11.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas RVMDW's P/E ratio is -1.55. In terms of profitability, TLX's ROE is -0.02%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, TLX is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for TLX.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
TLX vs RVMD Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, RVMD has a market cap of 43.3B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while RVMD trades at $203.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas RVMD's P/E ratio is -23.10. In terms of profitability, TLX's ROE is -0.02%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, TLX is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for TLX.Check RVMD's competition here
Seagen Inc. (NASDAQ: SGEN)
TLX vs SGEN Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas SGEN's P/E ratio is -57.19. In terms of profitability, TLX's ROE is -0.02%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, TLX is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for TLX.Check SGEN's competition here
BeOne Medicines AG (NASDAQ: ONC)
TLX vs ONC Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, ONC has a market cap of 37.1B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while ONC trades at $347.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas ONC's P/E ratio is 61.18. In terms of profitability, TLX's ROE is -0.02%, compared to ONC's ROE of +0.14%. Regarding short-term risk, TLX is less volatile compared to ONC. This indicates lower risk in terms of short-term price fluctuations for TLX.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
TLX vs ALNY Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, ALNY has a market cap of 30.6B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while ALNY trades at $228.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas ALNY's P/E ratio is 41.20. In terms of profitability, TLX's ROE is -0.02%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, TLX is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for TLX.Check ALNY's competition here
Insmed Incorporated (NASDAQ: INSM)
TLX vs INSM Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, INSM has a market cap of 26.8B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while INSM trades at $123.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas INSM's P/E ratio is -27.08. In terms of profitability, TLX's ROE is -0.02%, compared to INSM's ROE of -1.11%. Regarding short-term risk, TLX is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for TLX.Check INSM's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
TLX vs ROIV Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, ROIV has a market cap of 26.2B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while ROIV trades at $36.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas ROIV's P/E ratio is -34.44. In terms of profitability, TLX's ROE is -0.02%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, TLX is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for TLX.Check ROIV's competition here
Moderna, Inc. (NASDAQ: MRNA)
TLX vs MRNA Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, MRNA has a market cap of 25.1B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while MRNA trades at $63.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas MRNA's P/E ratio is -7.77. In terms of profitability, TLX's ROE is -0.02%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, TLX is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for TLX.Check MRNA's competition here
Incyte Corporation (NASDAQ: INCY)
TLX vs INCY Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, INCY has a market cap of 24.4B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while INCY trades at $120.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas INCY's P/E ratio is 16.15. In terms of profitability, TLX's ROE is -0.02%, compared to INCY's ROE of +0.30%. Regarding short-term risk, TLX is less volatile compared to INCY. This indicates lower risk in terms of short-term price fluctuations for TLX.Check INCY's competition here
BioNTech SE (NASDAQ: BNTX)
TLX vs BNTX Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, BNTX has a market cap of 23.4B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while BNTX trades at $93.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas BNTX's P/E ratio is -16.84. In terms of profitability, TLX's ROE is -0.02%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, TLX is less volatile compared to BNTX. This indicates lower risk in terms of short-term price fluctuations for TLX.Check BNTX's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
TLX vs UTHR Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, UTHR has a market cap of 21.2B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while UTHR trades at $499.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas UTHR's P/E ratio is 17.88. In terms of profitability, TLX's ROE is -0.02%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, TLX is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for TLX.Check UTHR's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
TLX vs BGNE Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas BGNE's P/E ratio is -22.55. In terms of profitability, TLX's ROE is -0.02%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, TLX is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for TLX.Check BGNE's competition here
Genmab A/S (NASDAQ: GMAB)
TLX vs GMAB Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, GMAB has a market cap of 19.6B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while GMAB trades at $31.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas GMAB's P/E ratio is 24.07. In terms of profitability, TLX's ROE is -0.02%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, TLX is less volatile compared to GMAB. This indicates lower risk in terms of short-term price fluctuations for TLX.Check GMAB's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
TLX vs DNA-WT Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, TLX's ROE is -0.02%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, TLX is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for TLX.Check DNA-WT's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
TLX vs BBIO Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, BBIO has a market cap of 15.6B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while BBIO trades at $79.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas BBIO's P/E ratio is -21.35. In terms of profitability, TLX's ROE is -0.02%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, TLX is less volatile compared to BBIO. This indicates lower risk in terms of short-term price fluctuations for TLX.Check BBIO's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
TLX vs ASND Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, ASND has a market cap of 15.4B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while ASND trades at $248.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas ASND's P/E ratio is -102.69. In terms of profitability, TLX's ROE is -0.02%, compared to ASND's ROE of -56.42%. Regarding short-term risk, TLX is less volatile compared to ASND. This indicates lower risk in terms of short-term price fluctuations for TLX.Check ASND's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
TLX vs JAZZ Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, JAZZ has a market cap of 15.4B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while JAZZ trades at $244.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas JAZZ's P/E ratio is 9.13. In terms of profitability, TLX's ROE is -0.02%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, TLX is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for TLX.Check JAZZ's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
TLX vs NBIX Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, NBIX has a market cap of 15.4B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while NBIX trades at $152.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas NBIX's P/E ratio is 22.07. In terms of profitability, TLX's ROE is -0.02%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, TLX is less volatile compared to NBIX. This indicates lower risk in terms of short-term price fluctuations for TLX.Check NBIX's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
TLX vs BMRN Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, BMRN has a market cap of 13B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while BMRN trades at $67.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas BMRN's P/E ratio is 32.38. In terms of profitability, TLX's ROE is -0.02%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, TLX is less volatile compared to BMRN. This indicates lower risk in terms of short-term price fluctuations for TLX.Check BMRN's competition here
Exelixis, Inc. (NASDAQ: EXEL)
TLX vs EXEL Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, EXEL has a market cap of 12.9B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while EXEL trades at $51.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas EXEL's P/E ratio is 14.64. In terms of profitability, TLX's ROE is -0.02%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, TLX is less volatile compared to EXEL. This indicates lower risk in terms of short-term price fluctuations for TLX.Check EXEL's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
TLX vs KRTX Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas KRTX's P/E ratio is -28.09. In terms of profitability, TLX's ROE is -0.02%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, TLX is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for TLX.Check KRTX's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
TLX vs ARWR Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, ARWR has a market cap of 12.2B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while ARWR trades at $86.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas ARWR's P/E ratio is -38.51. In terms of profitability, TLX's ROE is -0.02%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, TLX is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for TLX.Check ARWR's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
TLX vs MDGL Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, MDGL has a market cap of 11.7B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while MDGL trades at $507.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas MDGL's P/E ratio is -39.65. In terms of profitability, TLX's ROE is -0.02%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, TLX is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for TLX.Check MDGL's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
TLX vs HALO Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, HALO has a market cap of 11.7B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while HALO trades at $98.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas HALO's P/E ratio is 18.41. In terms of profitability, TLX's ROE is -0.02%, compared to HALO's ROE of +1.81%. Regarding short-term risk, TLX is less volatile compared to HALO. This indicates lower risk in terms of short-term price fluctuations for TLX.Check HALO's competition here
Bio-Techne Corporation (NASDAQ: TECH)
TLX vs TECH Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while TECH trades at $72.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas TECH's P/E ratio is 37.32. In terms of profitability, TLX's ROE is -0.02%, compared to TECH's ROE of +0.09%. Regarding short-term risk, TLX is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for TLX.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
TLX vs RNAM Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas RNAM's P/E ratio is -17.39. In terms of profitability, TLX's ROE is -0.02%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, TLX is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for TLX.Check RNAM's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
TLX vs AXSM Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, AXSM has a market cap of 11B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while AXSM trades at $213.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas AXSM's P/E ratio is -55.79. In terms of profitability, TLX's ROE is -0.02%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, TLX is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for TLX.Check AXSM's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
TLX vs SMMT Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, SMMT has a market cap of 10.6B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while SMMT trades at $13.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas SMMT's P/E ratio is -8.34. In terms of profitability, TLX's ROE is -0.02%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, TLX is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for TLX.Check SMMT's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
TLX vs PRAX Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, PRAX has a market cap of 10.2B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while PRAX trades at $366.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas PRAX's P/E ratio is -28.37. In terms of profitability, TLX's ROE is -0.02%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, TLX is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for TLX.Check PRAX's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
TLX vs PTGX Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, PTGX has a market cap of 10B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while PTGX trades at $155.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas PTGX's P/E ratio is 150.58. In terms of profitability, TLX's ROE is -0.02%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, TLX is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for TLX.Check PTGX's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
TLX vs KRYS Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, KRYS has a market cap of 9.8B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while KRYS trades at $332.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas KRYS's P/E ratio is 41.64. In terms of profitability, TLX's ROE is -0.02%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, TLX is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for TLX.Check KRYS's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
TLX vs KYMR Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, KYMR has a market cap of 9.7B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while KYMR trades at $117.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas KYMR's P/E ratio is -36.68. In terms of profitability, TLX's ROE is -0.02%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, TLX is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for TLX.Check KYMR's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
TLX vs RXDX Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas RXDX's P/E ratio is -56.47. In terms of profitability, TLX's ROE is -0.02%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, TLX is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for TLX.Check RXDX's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
TLX vs IONS Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, IONS has a market cap of 9.5B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while IONS trades at $57.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas IONS's P/E ratio is -33.28. In terms of profitability, TLX's ROE is -0.02%, compared to IONS's ROE of -1.11%. Regarding short-term risk, TLX is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for TLX.Check IONS's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
TLX vs CYTK Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, CYTK has a market cap of 9.1B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while CYTK trades at $74.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas CYTK's P/E ratio is -11.83. In terms of profitability, TLX's ROE is -0.02%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, TLX is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for TLX.Check CYTK's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
TLX vs NUVL Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas NUVL's P/E ratio is -21.79. In terms of profitability, TLX's ROE is -0.02%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, TLX is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for TLX.Check NUVL's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
TLX vs SYRE Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, SYRE has a market cap of 9B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while SYRE trades at $103.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas SYRE's P/E ratio is -53.14. In terms of profitability, TLX's ROE is -0.02%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, TLX is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for TLX.Check SYRE's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
TLX vs CRNX Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while CRNX trades at $84.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas CRNX's P/E ratio is -16.81. In terms of profitability, TLX's ROE is -0.02%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, TLX is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for TLX.Check CRNX's competition here
Abivax S.A. (NASDAQ: ABVX)
TLX vs ABVX Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, ABVX has a market cap of 8.7B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while ABVX trades at $118.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas ABVX's P/E ratio is -62.36. In terms of profitability, TLX's ROE is -0.02%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, TLX is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for TLX.Check ABVX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
TLX vs IMGN Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas IMGN's P/E ratio is -111.55. In terms of profitability, TLX's ROE is -0.02%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, TLX is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for TLX.Check IMGN's competition here
Immunovant, Inc. (NASDAQ: IMVT)
TLX vs IMVT Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, IMVT has a market cap of 8.6B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while IMVT trades at $41.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas IMVT's P/E ratio is -14.83. In terms of profitability, TLX's ROE is -0.02%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, TLX is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for TLX.Check IMVT's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
TLX vs PCVX Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, PCVX has a market cap of 8.4B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while PCVX trades at $58.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas PCVX's P/E ratio is -7.61. In terms of profitability, TLX's ROE is -0.02%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, TLX is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for TLX.Check PCVX's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
TLX vs BPMC Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas BPMC's P/E ratio is -51.58. In terms of profitability, TLX's ROE is -0.02%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, TLX is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for TLX.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
TLX vs APGE Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while APGE trades at $134.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas APGE's P/E ratio is -31.07. In terms of profitability, TLX's ROE is -0.02%, compared to APGE's ROE of -0.30%. Regarding short-term risk, TLX is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for TLX.Check APGE's competition here
Alkermes plc (NASDAQ: ALKS)
TLX vs ALKS Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, ALKS has a market cap of 8.2B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while ALKS trades at $49.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas ALKS's P/E ratio is 51.64. In terms of profitability, TLX's ROE is -0.02%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, TLX is less volatile compared to ALKS. This indicates lower risk in terms of short-term price fluctuations for TLX.Check ALKS's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
TLX vs CERE Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas CERE's P/E ratio is -16.47. In terms of profitability, TLX's ROE is -0.02%, compared to CERE's ROE of -0.72%. Regarding short-term risk, TLX is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for TLX.Check CERE's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
TLX vs IBRX Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, IBRX has a market cap of 7.9B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while IBRX trades at $7.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas IBRX's P/E ratio is -7.80. In terms of profitability, TLX's ROE is -0.02%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, TLX is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for TLX.Check IBRX's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
TLX vs RYTM Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, RYTM has a market cap of 7.9B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while RYTM trades at $115.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas RYTM's P/E ratio is -37.13. In terms of profitability, TLX's ROE is -0.02%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, TLX is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for TLX.Check RYTM's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
TLX vs TGTX Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, TGTX has a market cap of 7.5B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while TGTX trades at $48.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas TGTX's P/E ratio is 17.66. In terms of profitability, TLX's ROE is -0.02%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, TLX is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for TLX.Check TGTX's competition here
Metsera, Inc. (NASDAQ: MTSR)
TLX vs MTSR Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas MTSR's P/E ratio is -23.58. In terms of profitability, TLX's ROE is -0.02%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, TLX is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for TLX.Check MTSR's competition here
Merus N.V. (NASDAQ: MRUS)
TLX vs MRUS Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas MRUS's P/E ratio is -17.05. In terms of profitability, TLX's ROE is -0.02%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, TLX is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for TLX.Check MRUS's competition here
Arcellx, Inc. (NASDAQ: ACLX)
TLX vs ACLX Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas ACLX's P/E ratio is -28.27. In terms of profitability, TLX's ROE is -0.02%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, TLX is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for TLX.Check ACLX's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
TLX vs ORKA Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, ORKA has a market cap of 6.7B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while ORKA trades at $111.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas ORKA's P/E ratio is -57.24. In terms of profitability, TLX's ROE is -0.02%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, TLX is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for TLX.Check ORKA's competition here
CG Oncology Inc. (NASDAQ: CGON)
TLX vs CGON Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, CGON has a market cap of 6.6B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while CGON trades at $75.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas CGON's P/E ratio is -27.89. In terms of profitability, TLX's ROE is -0.02%, compared to CGON's ROE of -0.25%. Regarding short-term risk, TLX is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for TLX.Check CGON's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
TLX vs RETA Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas RETA's P/E ratio is -66.29. In terms of profitability, TLX's ROE is -0.02%, compared to RETA's ROE of +0.47%. Regarding short-term risk, TLX is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for TLX.Check RETA's competition here
Belite Bio, Inc (NASDAQ: BLTE)
TLX vs BLTE Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, BLTE has a market cap of 6.5B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while BLTE trades at $162.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas BLTE's P/E ratio is -87.06. In terms of profitability, TLX's ROE is -0.02%, compared to BLTE's ROE of -0.18%. Regarding short-term risk, TLX is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for TLX.Check BLTE's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
TLX vs DNTH Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, DNTH has a market cap of 6.5B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while DNTH trades at $115.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas DNTH's P/E ratio is -27.94. In terms of profitability, TLX's ROE is -0.02%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, TLX is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for TLX.Check DNTH's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
TLX vs COGT Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, COGT has a market cap of 6.5B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while COGT trades at $37.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas COGT's P/E ratio is -17.98. In terms of profitability, TLX's ROE is -0.02%, compared to COGT's ROE of -0.73%. Regarding short-term risk, TLX is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for TLX.Check COGT's competition here
Erasca, Inc. (NASDAQ: ERAS)
TLX vs ERAS Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, ERAS has a market cap of 6.4B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while ERAS trades at $18.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas ERAS's P/E ratio is -19.76. In terms of profitability, TLX's ROE is -0.02%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, TLX is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for TLX.Check ERAS's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
TLX vs SRRK Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, SRRK has a market cap of 6.3B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while SRRK trades at $52.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas SRRK's P/E ratio is -15.22. In terms of profitability, TLX's ROE is -0.02%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, TLX is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for TLX.Check SRRK's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
TLX vs CNTA Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas CNTA's P/E ratio is -22.63. In terms of profitability, TLX's ROE is -0.02%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, TLX is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for TLX.Check CNTA's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
TLX vs CAI Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, CAI has a market cap of 6.2B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while CAI trades at $21.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas CAI's P/E ratio is 61.25. In terms of profitability, TLX's ROE is -0.02%, compared to CAI's ROE of +0.19%. Regarding short-term risk, TLX is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for TLX.Check CAI's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
TLX vs MIRM Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, MIRM has a market cap of 6.1B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while MIRM trades at $100.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas MIRM's P/E ratio is -6.92. In terms of profitability, TLX's ROE is -0.02%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, TLX is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for TLX.Check MIRM's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
TLX vs XENE Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, XENE has a market cap of 6B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while XENE trades at $62.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas XENE's P/E ratio is -13.27. In terms of profitability, TLX's ROE is -0.02%, compared to XENE's ROE of -0.44%. Regarding short-term risk, TLX is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for TLX.Check XENE's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
TLX vs PTCT Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, PTCT has a market cap of 6B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while PTCT trades at $71.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas PTCT's P/E ratio is -30.77. In terms of profitability, TLX's ROE is -0.02%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, TLX is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for TLX.Check PTCT's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
TLX vs LGND Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, LGND has a market cap of 5.9B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while LGND trades at $294.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas LGND's P/E ratio is 32.34. In terms of profitability, TLX's ROE is -0.02%, compared to LGND's ROE of +0.20%. Regarding short-term risk, TLX is less volatile compared to LGND. This indicates lower risk in terms of short-term price fluctuations for TLX.Check LGND's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
TLX vs DFTX Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, DFTX has a market cap of 5.8B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while DFTX trades at $42.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas DFTX's P/E ratio is N/A. In terms of profitability, TLX's ROE is -0.02%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, TLX is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for TLX.Check DFTX's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
TLX vs TVTX Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, TVTX has a market cap of 5.8B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while TVTX trades at $62.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas TVTX's P/E ratio is -138.09. In terms of profitability, TLX's ROE is -0.02%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, TLX is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for TLX.Check TVTX's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
TLX vs CDTX Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas CDTX's P/E ratio is -19.77. In terms of profitability, TLX's ROE is -0.02%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, TLX is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for TLX.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
TLX vs ABCM Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, TLX's ROE is -0.02%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, TLX is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for TLX.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
TLX vs ISEE Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas ISEE's P/E ratio is -22.44. In terms of profitability, TLX's ROE is -0.02%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, TLX is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for TLX.Check ISEE's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
TLX vs APLS Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas APLS's P/E ratio is 38.35. In terms of profitability, TLX's ROE is -0.02%, compared to APLS's ROE of +0.40%. Regarding short-term risk, TLX is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for TLX.Check APLS's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
TLX vs CRSP Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, CRSP has a market cap of 5.2B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while CRSP trades at $53.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas CRSP's P/E ratio is -11.25. In terms of profitability, TLX's ROE is -0.02%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, TLX is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for TLX.Check CRSP's competition here
Dyne Therapeutics, Inc. (NASDAQ: DYN)
TLX vs DYN Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, DYN has a market cap of 4.8B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while DYN trades at $25.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas DYN's P/E ratio is -8.06. In terms of profitability, TLX's ROE is -0.02%, compared to DYN's ROE of -0.64%. Regarding short-term risk, TLX is less volatile compared to DYN. This indicates lower risk in terms of short-term price fluctuations for TLX.Check DYN's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
TLX vs ACAD Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, ACAD has a market cap of 4.8B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while ACAD trades at $28.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas ACAD's P/E ratio is 13.71. In terms of profitability, TLX's ROE is -0.02%, compared to ACAD's ROE of +0.32%. Regarding short-term risk, TLX is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for TLX.Check ACAD's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
TLX vs TERN Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas TERN's P/E ratio is -51.41. In terms of profitability, TLX's ROE is -0.02%, compared to TERN's ROE of -0.20%. Regarding short-term risk, TLX is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for TLX.Check TERN's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
TLX vs EWTX Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, EWTX has a market cap of 4.8B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while EWTX trades at $44.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas EWTX's P/E ratio is -23.88. In terms of profitability, TLX's ROE is -0.02%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, TLX is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for TLX.Check EWTX's competition here
Veradermics, Incorporated (NYSE: MANE)
TLX vs MANE Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, MANE has a market cap of 4.7B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while MANE trades at $112.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas MANE's P/E ratio is -35.90. In terms of profitability, TLX's ROE is -0.02%, compared to MANE's ROE of -0.29%. Regarding short-term risk, TLX is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for TLX.Check MANE's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
TLX vs FOLD Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas FOLD's P/E ratio is -161.00. In terms of profitability, TLX's ROE is -0.02%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, TLX is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for TLX.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
TLX vs AKRO Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas AKRO's P/E ratio is -14.57. In terms of profitability, TLX's ROE is -0.02%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, TLX is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for TLX.Check AKRO's competition here
Celcuity Inc. (NASDAQ: CELC)
TLX vs CELC Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, CELC has a market cap of 4.5B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while CELC trades at $92.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas CELC's P/E ratio is -23.59. In terms of profitability, TLX's ROE is -0.02%, compared to CELC's ROE of -3.51%. Regarding short-term risk, TLX is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for TLX.Check CELC's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
TLX vs ALPN Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas ALPN's P/E ratio is -101.52. In terms of profitability, TLX's ROE is -0.02%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, TLX is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for TLX.Check ALPN's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
TLX vs RLAY Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, RLAY has a market cap of 4.4B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while RLAY trades at $19.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas RLAY's P/E ratio is -12.65. In terms of profitability, TLX's ROE is -0.02%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, TLX is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for TLX.Check RLAY's competition here
Parabilis Medicines, Inc. (NASDAQ: PBLS)
TLX vs PBLS Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, PBLS has a market cap of 4.3B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while PBLS trades at $37.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas PBLS's P/E ratio is -42.12. In terms of profitability, TLX's ROE is -0.02%, compared to PBLS's ROE of N/A. Regarding short-term risk, TLX is less volatile compared to PBLS. This indicates lower risk in terms of short-term price fluctuations for TLX.Check PBLS's competition here
Opthea Limited (NASDAQ: OPT)
TLX vs OPT Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas OPT's P/E ratio is -1.52. In terms of profitability, TLX's ROE is -0.02%, compared to OPT's ROE of +1.18%. Regarding short-term risk, TLX is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for TLX.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
TLX vs PRTC Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas PRTC's P/E ratio is -3.78. In terms of profitability, TLX's ROE is -0.02%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, TLX is less volatile compared to PRTC. This indicates lower risk in terms of short-term price fluctuations for TLX.Check PRTC's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
TLX vs ELVN Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, ELVN has a market cap of 4.2B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while ELVN trades at $58.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas ELVN's P/E ratio is -35.22. In terms of profitability, TLX's ROE is -0.02%, compared to ELVN's ROE of -0.19%. Regarding short-term risk, TLX is less volatile compared to ELVN. This indicates lower risk in terms of short-term price fluctuations for TLX.Check ELVN's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
TLX vs TNGX Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, TNGX has a market cap of 4.2B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while TNGX trades at $25.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas TNGX's P/E ratio is -30.84. In terms of profitability, TLX's ROE is -0.02%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, TLX is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for TLX.Check TNGX's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
TLX vs MRTX Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas MRTX's P/E ratio is -4.82. In terms of profitability, TLX's ROE is -0.02%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, TLX is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for TLX.Check MRTX's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
TLX vs ADPT Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, ADPT has a market cap of 4B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while ADPT trades at $24.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas ADPT's P/E ratio is -60.34. In terms of profitability, TLX's ROE is -0.02%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, TLX is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for TLX.Check ADPT's competition here
Denali Therapeutics Inc. (NASDAQ: DNLI)
TLX vs DNLI Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, DNLI has a market cap of 3.9B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while DNLI trades at $24.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas DNLI's P/E ratio is -8.47. In terms of profitability, TLX's ROE is -0.02%, compared to DNLI's ROE of -0.55%. Regarding short-term risk, TLX is less volatile compared to DNLI. This indicates lower risk in terms of short-term price fluctuations for TLX.Check DNLI's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
TLX vs VKTX Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, VKTX has a market cap of 3.9B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while VKTX trades at $33.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas VKTX's P/E ratio is -8.02. In terms of profitability, TLX's ROE is -0.02%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, TLX is less volatile compared to VKTX. This indicates lower risk in terms of short-term price fluctuations for TLX.Check VKTX's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
TLX vs CPRX Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas CPRX's P/E ratio is 12.30. In terms of profitability, TLX's ROE is -0.02%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, TLX is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for TLX.Check CPRX's competition here
Legend Biotech Corporation (NASDAQ: LEGN)
TLX vs LEGN Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, LEGN has a market cap of 3.8B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while LEGN trades at $20.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas LEGN's P/E ratio is -29.96. In terms of profitability, TLX's ROE is -0.02%, compared to LEGN's ROE of -0.09%. Regarding short-term risk, TLX is less volatile compared to LEGN. This indicates lower risk in terms of short-term price fluctuations for TLX.Check LEGN's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
TLX vs RYZB Comparison August 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, TLX is priced at $11.82 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of -642.39, whereas RYZB's P/E ratio is -57.86. In terms of profitability, TLX's ROE is -0.02%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, TLX is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for TLX.Check RYZB's competition here